Research Analysts Set Expectations for Genelux Co.’s Q1 2024 Earnings (NASDAQ:GNLX)

Genelux Co. (NASDAQ:GNLXFree Report) – Research analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of Genelux in a note issued to investors on Tuesday, April 2nd. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.25) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.03) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.42) EPS.

Separately, Benchmark reiterated a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a report on Wednesday.

Get Our Latest Research Report on GNLX

Genelux Stock Performance

Shares of GNLX stock opened at $4.86 on Thursday. The company’s 50-day simple moving average is $7.50 and its two-hundred day simple moving average is $13.19. Genelux has a one year low of $4.86 and a one year high of $40.98.

Institutional Investors Weigh In On Genelux

Several institutional investors and hedge funds have recently made changes to their positions in GNLX. Amalgamated Bank increased its position in shares of Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after acquiring an additional 770 shares during the period. California State Teachers Retirement System purchased a new stake in Genelux during the 2nd quarter valued at about $30,000. Tower Research Capital LLC TRC purchased a new stake in Genelux during the 1st quarter valued at about $32,000. Legal & General Group Plc increased its holdings in shares of Genelux by 535.2% in the third quarter. Legal & General Group Plc now owns 1,696 shares of the company’s stock valued at $41,000 after purchasing an additional 1,429 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Genelux by 2,105.0% in the second quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock worth $72,000 after purchasing an additional 2,105 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Company Profile

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Featured Articles

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.